Autres langues Iterum Therapeutics plc

Actions

ITRM

IE000TTOOBX0

Temps Différé Nasdaq Autres places de cotation 18:19:38 01/05/2024			Varia. 5j.	Varia. 1 janv.
1,502 ^USD	-1,84 %		-3,11 %	-23,77 %

29/04	Iterum Therapeutics dépose à nouveau une demande de nouveau médicament auprès de la Food and Drug Administration américaine pour le sulopenem oral	CI
28/03	Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	28/03
Iterum Therapeutics plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/03
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	21/03
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat	15/03
Iterum Therapeutics Provides Business Update	06/03
Iterum Therapeutics Plans to Engage Financial Advisor to Evaluate Strategic Alternatives	06/03
Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint	30/01
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	30/01
Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections	30/01
Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023	29/12
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule	04/12
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Iterum Therapeutics Reports Third Quarter 2023 Financial Results	14/11
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	07/11
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24/10/23
Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24/10/23
Iterum Therapeutics to Present Data at IDWeek 2023	12/10/23
Iterum Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	02/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Iterum Therapeutics plc

Actions

ITRM

IE000TTOOBX0

Autres langues

Filtres